Physician profile
Kristin Davis
NPI 1679693907
$6,985.39
in general payments reported to CMS, 2019-2025
36 companies · $644 in 2025
The $644 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $909 · 2020: $864 · 2021: $976 · 2022: $978 · 2023: $991 · 2024: $1,624 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,189 · Education: $55.54 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,188.54 |
| Education | $55.54 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,707.09 | 2020-2025 | Botox, Qulipta, Duopa |
| Teva Pharmaceuticals USA, INC. | $769.81 | 2019-2023 | Austedo |
| Mdd US Operations, LLC | $671.78 | 2019-2025 | Gocovri |
| Pfizer INC. | $502.51 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $470.30 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $361.28 | 2019-2020 | |
| Allergan, INC. | $307.59 | 2019-2022 | |
| Impel Pharmaceuticals INC. | $280.59 | 2022-2023 | Trudhesa |
| Abbott Laboratories | $223.32 | 2023-2025 | Proclaim, Infinity |
| Octapharma USA, INC. | $218.17 | 2023-2025 | Panzyga |
| Lundbeck LLC | $202.57 | 2019-2024 | Vyepti |
| Celgene Corporation | $108.82 | 2023-2025 | Zeposia |
| Emd Serono, INC. | $105.39 | 2020-2021 | |
| Boston Scientific Corporation | $101.04 | 2021-2024 | Vercise |
| Ge Healthcare | $96.78 | 2019-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $90.42 | 2020-2023 | Spinraza |
| Amgen INC. | $89.06 | 2019-2025 | Uplizna |
| Acadia Pharmaceuticals INC | $85.82 | 2019-2025 | Nuplazid |
| Medtronic, INC. | $80.29 | 2021-2023 | Activa PC |
| Merz Pharmaceuticals, LLC | $55.54 | 2023 | Xeomin |
| Eisai INC. | $46.31 | 2019-2021 | |
| Genentech USA, INC. | $46.31 | 2020 | |
| Ucb, INC. | $42.31 | 2022-2023 | Briviact |
| Alexion Pharmaceuticals, INC. | $38.83 | 2023 | |
| Greenwich Biosciences, INC. | $31.64 | 2019 | |
| Livanova USA, INC. | $30.93 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Amneal Pharmaceuticals LLC | $29.50 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $27.07 | 2021 | |
| Genzyme Corporation | $24.21 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $23.36 | 2023 | Rexulti |
| Kyowa Kirin, INC. | $23.08 | 2021 | |
| Jazz Pharmaceuticals INC. | $22.30 | 2021 | |
| Revance Therapeutics, INC. | $21.08 | 2024 | Daxxify |
| Axsome Therapeutics, INC. | $20.42 | 2024 | Sunosi |
| Avanir Pharmaceuticals, INC. | $17.07 | 2022 | |
| Insightec,INC | $12.80 | 2023 | Exablate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.